醋酸甲羟孕酮作为GnRH拮抗剂的替代方案用于社会性生育力保存和PGT-A的卵母细胞玻璃化
多中心回顾性观察性队列研究显示,在社会性生育力保存和PGT-A周期中,使用醋酸甲羟孕酮(MPA)的孕激素促排卵方案与GnRH拮抗剂相比,获卵数、整倍体率和持续妊娠率相似,而拮抗剂组临床流产率更高。作者认为PPOS可推荐用于上述周期的卵巢刺激。
要点
- 社会性生育力保存周期中,MPA组与拮抗剂组成熟卵母细胞玻璃化数相似,无论年龄≤35岁或>35岁。
- PGT-A周期中,MPA组与拮抗剂组的MII卵数、2PN数、活检胚胎数、整倍体率和持续妊娠率无显著差异。
- PGT-A周期中拮抗剂组临床流产率高于MPA组(14.8% vs 10.4%,P=0.019)。
核心结论
- PPOS方案在获卵数、整倍体胚胎率和临床结局方面与GnRH拮抗剂相似,作者认为可推荐用于社会性生育力保存和PGT-A周期的卵巢刺激,因其让患者更舒适。
研究设计与样本
- 多中心、回顾性、观察性队列研究,在11个隶属于私立大学的IVIRMA中心进行。
- 社会性生育力保存共1652个周期,其中267例使用孕激素促排卵方案(PPOS,MPA),1385例使用GnRH拮抗剂;另有66个周期取消。
- PGT-A共分析5661个治疗周期,其中635例使用MPA,5026例使用GnRH拮抗剂;另有1299个周期取消。
- 所有周期在2019年6月至2021年12月间进行。
主要发现
- 社会性生育力保存周期中,MPA组与拮抗剂组玻璃化成熟卵母细胞数相似,无论年龄≤35岁或>35岁均见该趋势。
- PGT-A周期中,MPA组与拮抗剂组的MII卵数、2PN数无差异。
- PGT-A周期中,MPA组与拮抗剂组的活检胚胎数分别为4.4±3.1 vs 4.5±3.1,整倍体率分别为57.9% vs 56.4%。
- PGT-A周期中,MPA组与拮抗剂组的持续妊娠率分别为50.4% vs 47.1%(P=0.119),无显著差异。
- PGT-A周期中,拮抗剂组临床流产率高于MPA组(14.8% vs 10.4%,P=0.019)。
临床怎么用
- 作者认为PPOS可推荐用于社会性生育力保存和PGT-A周期的卵巢刺激,因其让患者更舒适。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Can medroxyprogesterone acetate (MPA) be used as a pituitary suppressor instead of a gonadotrophin releasing hormone (GnRH) antagonist during ovarian stimulation in elective fertility preservation and preimplantation genetic testing for aneuploidy (PGT-A) cycles? DESIGN: A multicentre, retrospective, observational, cohort study conducted in 11 IVIRMA centres affiliated to private universities. Of a total of 1652 cycles of social fertility preservation, 267 patients were stimulated using a progestin-primed ovarian stimulation protocol (PPOS), and 1385 patients received a GnRH antagonist. In the PGT-A cycles, 5661 treatments were analysed: 635 patients received MPA and 5026 patients received GnRH antagonist. A further 66 fertility preservation and 1299 PGT-A cycles were cancelled. All cycles took place between June 2019 and December 2021. RESULTS: In the social fertility preservation cycles, the number of mature oocytes vitrified in MPA was similar to the number of those treated with an antagonist, a trend that was seen regardless of age (≤35 or >35 years). In the PGT-A cycles, no differences were found in number of metaphase II, two pronuclei, number of biopsied embryos (4.4 ± 3.1 versus 4.5 ± 3.1), rate of euploidy (57.9% versus 56.4%) or ongoing pregnancy rate (50.4% versus 47.1%, P = 0.119) between the group receiving MPA versus a GnRH antagonist, whereas the clinical miscarriage rate was higher in the antagonist group (10.4% versus 14.8%, P = 0.019). CONCLUSIONS: Administration of PPOS yields similar results to GnRH antagonists in oocytes retrieved, rate of euploid embryos and clinical outcome. Hence, PPOS can be recommended for ovarian stimulation in social fertility preservation and PGT-A cycles, as it allows greater patient comfort.
引用
- Giles J, Cruz M, Cobo A, et al. Medroxyprogesterone acetate: an alternative to GnRH-antagonist in oocyte vitrification for social fertility preservation and preimplantation genetic testing for aneuploidy. Reprod Biomed Online. 2023. PMID: 37290978. doi:10.1016/j.rbmo.2023.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。